The company is currently focused on developing therapeutic and diagnostic product opportunities based on three proprietary technologies:
Prokineticin signaling molecules and receptors involved in multiple physiological processes including circadian rhythm regulation, GI motility, and neurogenesis.
Antibodies and vaccines for soluble oligomeric forms of amyloid proteins involved in multiple pathologic states including Alzheimers disease, age-related macular degeneration (AMD), and diabetes.
Small molecule antagonists of the melanin concentrating hormone receptor 1 (MCHR1) as potential therapies for obesity and eating disorders.
Intellectual property and know-how for these programs has been licensed exclusively to Kinexis by the University of California, Irvine.
